ArticleVisceral medicine2025
Sectional Imaging for Alveolar Echinococcosis.
Article in Visceral medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Alveolar Echinococcosis in the Early 2020s: A Systematic Review.Pathogens (Basel, Switzerland) · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Alveolar echinococcosis (AE) is a rare but potentially life-threatening parasitic disease caused by the larval stage of Methods: We retrospectively analyzed all patients who presented with suspected AE at the University Hospital Ulm between January 2019 and December 2023 and had F-18-fluorodeoxyglucose positron emission tomography (F-18-FDG-PET/computed tomography [CT] or PET/ magnetic resonance imaging [MRI]) and/or MRI within 6 months of presentation. PET imaging was visually assessed for increased FDG uptake as a marker of metabolic activity. Lesions were classified according to the Kodama MRI classification. Imaging-based staging was performed using the PNM classification and compared with the clinical PNM stage. Results: A total of 203 patients were included. PET imaging was performed in 198 cases (97.5%), while MRI was available in 94 patients (46.3%). Kodama types 2 ( Conclusion: F-18-FDG-PET/CT is a cornerstone in the initial diagnostic workup and staging of AE, enabling both assessment of disease extent and evaluation of inflammatory activity in specialized centers. While MRI provides essential morphological details, its limited availability and heterogeneous acquisition protocols reduce its utility for comprehensive staging. Kodama lesion types correlate with metabolic activity, but further studies are needed to clarify their prognostic relevance. Our findings underscore the importance of standardized imaging protocols and the central role of PET/CT in managing newly diagnosed AE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.